Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares of Stock

by · The Cerbat Gem

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) EVP Michael Feld sold 75 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $152.80, for a total value of $11,460.00. Following the transaction, the executive vice president directly owned 21,009 shares in the company, valued at approximately $3,210,175.20. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

  • On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $147.35, for a total value of $11,051.25.
  • On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $151.94, for a total value of $11,243.56.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $156.06 on Friday. The business’s fifty day moving average is $148.17 and its 200 day moving average is $170.75. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market cap of $43.00 billion, a P/E ratio of 39.51, a P/E/G ratio of 10.72 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the business posted $3.35 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently made changes to their positions in the business. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company during the third quarter valued at $25,000. Steph & Co. raised its stake in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares during the period. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $26,000. Prosperity Bancshares Inc bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $29,000. Finally, WPG Advisers LLC grew its stake in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 61 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a report on Tuesday, April 14th. Bank of America lowered their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Piper Sandler dropped their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Evercore upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $181.00.

View Our Latest Analysis on BDX

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Further Reading